摘要
阿糖胞苷为成年人急性髓细胞白血病（AML）化疗的基础用药。对于全部AML成年患者，特别是核心结合因子（CBF）相关、伴有t（8；21）（q22；q22）核型与inv（16）/t（16；16）核型的AML成年患者，应用4个疗程大剂量阿糖胞苷（HDAC）方案能够有效改善其预后。伴有RAS基因突变的AML成年患者亦能够从HDAC方案治疗中获益。但是在成年人AML巩固化疗中，阿糖胞苷最适疗程、累积剂量、单药或者多药联合应用（MCT）等问题，仍尚在不断探索中。随着针对特定基因突变的新型靶向治疗药物不断涌现，阿糖胞苷在成年人AML巩固化疗中的治疗方案有待进一步优化。笔者拟就阿糖胞苷在成年人AML巩固化疗中的应用及研究进展进行阐述。
Cytarabine plays a pivotal role in chemotherapy for adult acute myeloid leukemia （AML）. For all AML adult patients, especially core binding factor （CBF） AML adult patients, and AML adult patients with t（8; 21）（q22; q22） karyotype and inv（16）/t（16; 16） karyotype, application of 4 courses of high dose of cytarabine （HDAC） can effectively improve the prognosis. AML adult patients with RAS mutation also tend to benefit from HDAC. However, in the consolidation chemotherapy in AML adult patients, issues like optimal course of treatment, cumulative dose, single drug or multiagent chemotherapy （MCT） of cytarabine are still being explored. With the application of newly-developed drugs as targeting certain gene mutations, treatment regimens of cytarabine still need to be optimized. This article focuses on application research progress of cytarabine in the consolidation chemotherapy of AML adult patients and its studying current status.
作者
张益敏
胡晓霞
Zhang Yimin , Hu Xiaoxia(Department of Hematology, Changhai Hospital, Second Military Medical University ~ Institute of Hematologic Disease of Chinese PLA, Shanghai 200433, Chin)
出处
《国际输血及血液学杂志》
CAS
2018年第1期2-9,共8页
International Journal of Blood Transfusion and Hematology
基金
国家自然科学基金（81470321、81770160）
上海市卫生计生委卫生系统优秀学科带头人培养计划（2017BR012）
关键词
白血病
髓样
急性
阿糖胞苷
药物疗法
抗肿瘤联合化疗方案
Leukemia, myeloid, acute
Cytarabine
Drug therapy
Antineoplastic combined chemotherapy protocol
